Trials / Unknown
UnknownNCT02587884
Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH
Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Eastern Hepatobiliary Surgery Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to explore the effect of Transarterial Chemoembolization (TACE) on the prognosis of patients with microvascular invasion presence(MVI) and overexpression of Aspartate-β-hydroxylase(ASPH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | TACE | Patients will treated by TACE in 4 or 8 weeks after operation. |
Timeline
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2015-10-27
- Last updated
- 2016-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02587884. Inclusion in this directory is not an endorsement.